Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 17, 2015 11:43 PM ET

Pharmaceuticals

Company Overview of Zyngenia, Inc.

Executive Profile

Peter A. Kiener D.Phil.

Chief Science Officer, Sucampo Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 5 Board Members in 5 different organizations across 11 different industries.

See Board Relationships
62$1,812,214
As of Fiscal Year 2014

Background

Dr. Peter A. Kiener, D.Phil. has been the Chief Science Officer at Sucampo Pharmaceuticals, Inc. since October 27, 2014. Dr. Kiener was a Co-Founder of Zyngenia, Inc. Dr. Kiener served as Chief Executive Officer and President of Zyngenia, Inc. and leads business and drug development efforts. Dr. Kiener served as Chief Scientific Officer of Ambrx, Inc. since August 2013. Dr. Kiener served as a Board Observer of Virdante Pharmaceuticals, Inc. He served as an Executive ...

Corporate Headquarters

21 Firstfield Road
Gaithersburg, Maryland 20878

United States

Phone: 410-467-1176
Fax: --

Board Members Memberships

Former Director
Former Board Observer
Former Chief Executive Officer, President and Director
Chairman

Education

PhD
University of Oxford
BS
Lancaster University

Other Affiliations

Annual Compensation

Salary$72,000
Bonus$100,000
Total Annual Compensation$172,000

Stocks Options

All Other Compensation$9,030
Unexercisable Options$300,000
Unexercisable Options Value$1,785,000
Total Value of Options$1,785,000
Total Number of Options$300,000

Total Compensation

Total Annual Cash Compensation$217,894
Total Short Term Compensation$172,000
Other Long Term Compensation$9,030
Total Calculated Compensation$1,812,214
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Howard W. Robin Chief Executive Officer, President and Director
Nektar Therapeutics
$831.2K
Mark R. Baker J.D.Chief Executive Officer, Director and Member of Science & Strategy Committee
Progenics Pharmaceuticals, Inc.
$535.6K
Craig A. Wheeler Chief Executive Officer, President and Executive Director
Momenta Pharmaceuticals Inc.
$621.0K
Douglas L. Drysdale Chairman, Chief Executive Officer and President
Pernix Therapeutics Holdings, Inc.
--
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Zyngenia, Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.